---
title: Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease
  and warm antibody autoimmune hemolytic anemia
date: '2024-11-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39486046/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241101195434&v=2.18.0.post9+e462414
source: Blood
description: Cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic
  anemia (wAIHA) are rare autoimmune hemolytic anemias characterized by red blood
  cell destruction, largely attributable to complement activation resulting in intravascular
  and extravascular hemolysis. Pegcetacoplan is a subcutaneously administered C3-targeted
  therapy, which may be suitable for treating CAD and wAIHA. In this open-label phase
  2 study, analyses were conducted in two cohorts, one for patients with CAD and the
  ...
disable_comments: true
---
Cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) are rare autoimmune hemolytic anemias characterized by red blood cell destruction, largely attributable to complement activation resulting in intravascular and extravascular hemolysis. Pegcetacoplan is a subcutaneously administered C3-targeted therapy, which may be suitable for treating CAD and wAIHA. In this open-label phase 2 study, analyses were conducted in two cohorts, one for patients with CAD and the ...